Home
Conditions
Lymphoproliferative Disorders

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,031 public trials 2,028 recruiting studies

Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Active, Not Recruiting

Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML

NCT02094794

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), +22 more
Locations: City of Hope Medical Center Duarte, California, United States

View Trial Details

Active, Not Recruiting

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04162210

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: GSK Investigational Site Tucson, Arizona, United States

GSK Investigational Site Pueblo, Colorado, United States

GSK Investigational Site Detroit, Michigan, United States

GSK Investigational Site Omaha, Nebraska, United States

View all 136 locations

View Trial Details

Active, Not Recruiting

Economic Analysis of Alliance A041202 CLL Study

NCT02414022

Conditions: Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations: Tom Baker Cancer Centre Calgary, Alberta, Canada

The Moncton Hospital Moncton, New Brunswick, Canada

Health Sciences North Greater Sudbury, Ontario, Canada

Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada

View all 15 locations

View Trial Details

Active, Not Recruiting

Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)

NCT06040320

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations: Washington University School of Medicine St Louis, Missouri, United States

View Trial Details

Active, Not Recruiting

Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies

NCT03241940

Conditions: B Acute Lymphoblastic Leukemia, Burkitt Lymphoma, CD19 Positive, +29 more
Locations: Lucile Packard Children's Hospital Stanford University Palo Alto, California, United States

View Trial Details

Active, Not Recruiting

Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT06824701

Conditions: Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations: Huntsman Cancer Institute at University of Uta Salt Lake City, Utah, United States

View Trial Details

Active, Not Recruiting

Implementation and Evaluation of an Internet-Based Stress Management Program for Health Students in the Sfax Region

NCT07123311

Conditions: Anxiety Depression (Mild or Not Persistent), Behavior, Hemic and Lymphatic Diseases, +11 more
Locations: Faculties of Sealth Sciences Sfax, Tunisia

View Trial Details

Active, Not Recruiting

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

NCT03805932

Conditions: Hairy Cell Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations: National Institutes of Health Clinical Center Bethesda, Maryland, United States

View Trial Details

Active, Not Recruiting

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

NCT05683171

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +5 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

NCT05058404

Conditions: Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations: IRCCS Istituto Romagnolo per lo studio dei Tumori "Dino Amadori" - IRST S.R.L. - Ematologia Meldola, Forlì - Cesena, Italy

U.O.C. Ematologia Ospedale Civile di Legnano Legnano, Milano, Italy

Nuovo Ospedale Civile di Sassuolo - Day Hospital Oncologico Sassuolo, Modena, Italy

ASST MONZA Ospedale S. Gerardo - Ematologia Monza, Monza E Brianza, Italy

View all 54 locations

View Trial Details

Lymphoproliferative Disorders

Lymphoproliferative Disorders trial results

Related conditions